"Spare-spleen-uximab" for chronic ITP

Blood

Volumn 112, Issue 4, 2008, Pages 925-926

  Warkentin, Theodore E ^a   Arnold, Donald M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN; RITUXIMAB;

ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NOTE; PRIORITY JOURNAL; SERUM SICKNESS; SPLENECTOMY; THROMBOCYTE COUNT; TREATMENT RESPONSE;

EID: 61649083351     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-159335     Document Type: Note

References (7)

1. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25-33.
2. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143-151.
3. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti- CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125:232-239.
4. Stasi R, Del Poeta G,Stipa E, etal. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocyto-penic purpura. Blood. 2007;110:2924-2930.
5. Cooper N, Evangelista ML, Amadori S, StasiR. Should rituximab be used before or after splenectomy in patients withimmunethrombocytopenicpurpura?Curr Opin Hematol. 2007;14:642-646.
6. Simanek R, Panzer S, Lechner K, Pabinger I. Late spontaneous remissions in severe adult autoimmune thrombocytopenia. Ann Hematol. 2007;86:705-710.
7. Rodeghiero F. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. Eur J Haematol. 2008;80(suppl. 69):19-26.